Showing results (81-90 of 94) with videos related to
Sort By:
Pageof 10
Future Oncology (London, England)|October 31, 2019
A Phase I/Ib trial of Ad-REIC in liver cancer: study protocolAstushi Oyama, Hidenori Shiraha, Daisuke Uchida, et al.Endocrinology|June 6, 2009
Up-regulation of alpha5-integrin by E-cadherin loss in hypoxia and its key role in the migration of extravillous trophoblast cells during early implantationEmi Arimoto-Ishida, Masahiro Sakata, Kenjiro Sawada, et al.The Journal of Biological Chemistry|March 18, 2004
Inhibition of NFkappaB increases the efficacy of cisplatin in in vitro and in vivo ovarian cancer modelsSeiji Mabuchi, Masahide Ohmichi, Yukihiro Nishio, et al.Molecular Medicine Reports|April 8, 2011
Redox state of albumin is not associated with colloid osmotic pressureMasahiro Sakata, Takumi Kawaguchi, Eitaro Taniguchi, et al.International Journal of Hematology|April 28, 2021
Transformation to diffuse large B-cell lymphoma with germinal center B-cell like subtype and discordant light chain expression in a patient with Waldenström macroglobulinemia/lymphoplasmacytic lymphomaHiroki Kobayashi, Noboru Asada, Yuria Egusa, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 2004
Inhibition of inhibitor of nuclear factor-kappaB phosphorylation increases the efficacy of paclitaxel in in vitro and in vivo ovarian cancer modelsSeiji Mabuchi, Masahide Ohmichi, Yukihiro Nishio, et al.Liver International : Official Journal of the International Association for the Study of the Liver|March 15, 2024
Predictive factors for transition to conversion therapy in hepatocellular carcinoma using atezolizumab plus bevacizumabTatsuya Kikuchi, Yasuto Takeuchi, Kazuhiro Nouso, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|February 9, 2026
Borderline Resectable Classification Identifies Candidates for Conversion Therapy in Unresectable Hepatocellular Carcinoma Treated With Atezolizumab and BevacizumabYasuto Takeuchi, Masahiko Sue, Nozomi Miyake, et al.Journal of Gastroenterology and Hepatology|April 16, 2014
CD34(+) cell therapy is safe and effective in slowing the decline of hepatic reserve function in patients with decompensated liver cirrhosisToru Nakamura, Takuji Torimura, Hideki Iwamoto, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|February 17, 2021
Abnormal fucosylation of alpha-fetoprotein in patients with nonalcoholic steatohepatitisKazuhiro Nouso, Yoshie Furubayashi, Kazuya Kariyama, et al.Pageof 10